Global neuroendocrine tumor market is expected to escalate in the forecast period, 2022-2026 on the account of rising prevalence of the neuroendocrine tumors all around the world. Also, research and development carried around for the diagnosing procedure like genetic sequencing for the neuroendocrine tumor is driving the growth of the global neuroendocrine tumor market in the upcoming five years. Globally, cases of gastrointestinal neuroendocrine carcinoma, and lung neuroendocrine carcinoma are prevailing at a very rapid rate which in turn has instigated the increasing research and development of the next-generation sequencing methods that are utilized for the development of treatment therapies of the neuroendocrine tumors. Furthermore, government aid toward rising demand for various imaging technique, drug portfolio expansion, and development of advanced related devices are expected to drive the market growth.

The global neuroendocrine tumor market segmentation is based on therapy type, mechanism of action, drug type, indication, route of administration, end user, regional distribution, and competitional landscape. Based on therapy type, the market is further bifurcated into chemotherapy, immunotherapy, hormonal therapy, surgery, targeted therapy, and others. Chemotherapy is a procedure that involves the treatment with a mix of chemicals that are designed specifically for the cancerous cells. Immunotherapy is the procedure where the treatment is given to the immune system by supplying white blood cells and support to the lymph and other immune organs. Hormonal therapy is similar and is supplied with growth restricting hormones, that can stunt the growth of cancer cells thereby holding the multiplication of cancerous tumors. Surgery is the best method for the cancer, in this process the cancerous cells are surgically removed such that no more cancer cells are left to multiply. Although, if the cancer is spreading due to genetic disorder, or if any cancerous cell is left in the body, the relapse chances multiply.

Partial list of major competitors in the global neuroendocrine tumor market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb AB, Eli Lilly & Company, Novartis AG, Pfizer Inc., Amgen, Inc., Exelixis Inc., Teva Pharmaceuticals Ltd., Callisto Pharmaceuticals Pvt. Ltd., Boehringer Ingelheim GmbH, Dauntless Pharmaceuticals Inc., Hutchison MediPharma Limited, AVEO Pharmaceuticals, Inc., Aegis Therapeutics LLC, Progenics Pharmaceuticals, Inc. among others. Top players are actively involved in the research and development of the devices as well as the procedural advancements such that technically advanced processes can aid the market. Other strategic recommendations include partnerships and takeovers.

Years considered for this report:

Historical Years: 2016 – 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 – 2026

Objective of the Study:

  • To analyze the historical growth of the market size of global neuroendocrine tumor market from 2016 to 2019.
  • To estimate and forecast the market size of global neuroendocrine tumor market from 2020 to 2026 and growth rate until 2026. 
  • To classify and forecast global neuroendocrine tumor market based on therapy type, mechanism of action, drug type, indication, route of administration, end user, regional distribution, and competitional landscape.
  • To identify dominant region or segment in the global neuroendocrine tumor market.
  • To identify drivers and challenges for global neuroendocrine tumor market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neuroendocrine tumor market.
  • To identify and analyze the profile of leading players operating in global neuroendocrine tumor market.
  • To identify key sustainable strategies adopted by market players in global neuroendocrine tumor market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global neuroendocrine tumor market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of products and other stakeholders
  • Organizations, forums, and alliances related to neuroendocrine tumor market  
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as vendors, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neuroendocrine tumor market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Neuroendocrine Tumor Market, By Therapy Type:
    • Chemotherapy
    • Immunotherapy
    • Hormonal Therapy
    • Surgery
    • Targeted Therapy
    • Others
  • Global Neuroendocrine Tumor Market, By Mechanism of Action:
    • Somatostatin Analogs
    • Tyrosine Kinase Inhibitor
    • Peptide Receptor Radionuclide
    • Alfa-Interferon
    • Proton Pump Inhibitors
    • Others
  • Global Neuroendocrine Tumor Market, By Drug Type:
    • Everolimus
    • Sunitib malate
    • Lorlatinib
    • Nivolumab
    • Bevacizumab
    • Others
  • Global Neuroendocrine Tumor Market, By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Appendiceal NET
    • Others
  • Global Neuroendocrine Tumor Market, By Route of Administration:
    • Oral
    • Parenteral
    • Others
  • Global Neuroendocrine Tumor Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Oncology Centers
    • Others
      • GI centers
      • Cardio-thoracic centers
      • NET centers
  • Global Neuroendocrine Tumor Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neuroendocrine tumor market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Neuroendocrine Tumor Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Neuroendocrine Tumors Treatment Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Neuroendocrine Tumors Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapy Type (Chemotherapy, Immunotherapy, Hormonal Therapy, Surgery, Targeted Therapy, Others)

6.2.2.     By Mechanism of Action (Somatostatin Analogs, Tyrosine Kinase Inhibitor, Peptide receptor radionuclide, Alfa-interferon, Proton pump inhibitors, Others)

6.2.3.     By Drug Type (Everolimus, Sunitib malate, Lorlatinib, Nivolumab, Bevacizumab, Others) 

6.2.4.     By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Appendiceal NET, Others)

6.2.5.     By Route of administration (Oral, Parenteral, Others)

6.2.6.     By End User (Hospitals, Ambulatory Surgical Centers, Oncology Centers, Others (GI centers, Cardio-thoracic centers, NET centers)

6.2.7.     By Company (2020)

6.2.8.     By Region

6.3.  Product Market Map

7.    Asia-Pacific Neuroendocrine Tumors Treatment Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapy Type

7.2.2.     By Mechanism of Action

7.2.3.     By Drug Type

7.2.4.     By Indication

7.2.5.     By Route of administration

7.2.6.     By End User

7.2.7.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Neuroendocrine Tumors Treatment Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapy Type

7.3.1.2.2.             By Mechanism of action

7.3.1.2.3.             By Drug Type

7.3.1.2.4.             By Indication

7.3.1.2.5.             By Route od administration

7.3.1.2.6.             By End User

7.3.2.     India Neuroendocrine Tumors Treatment Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapy Type

7.3.2.2.2.             By Mechanism of action

7.3.2.2.3.             By Drug Type

7.3.2.2.4.             By Indication

7.3.2.2.5.             By Route od administration

7.3.2.2.6.             By End User

7.3.3.     Japan Neuroendocrine Tumors Treatment Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapy Type

7.3.3.2.2.             By Mechanism of action

7.3.3.2.3.             By Drug Type

7.3.3.2.4.             By Indication

7.3.3.2.5.             By Route od administration

7.3.3.2.6.             By End User

7.3.4.     South Korea Neuroendocrine Tumors Treatment Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Therapy Type

7.3.4.2.2.             By Mechanism of action

7.3.4.2.3.             By Drug Type

7.3.4.2.4.             By Indication

7.3.4.2.5.             By Route od administration

7.3.4.2.6.             By End User

7.3.5.     Australia Neuroendocrine Tumors Treatment Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Therapy Type

7.3.5.2.2.             By Mechanism of action

7.3.5.2.3.             By Drug Type

7.3.5.2.4.             By Indication

7.3.5.2.5.             By Route od administration

7.3.5.2.6.             By End User

8.    Europe Neuroendocrine Tumors Treatment Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapy Type

8.2.2.     By Mechanism of Action

8.2.3.     By Drug Type

8.2.4.     By Indication

8.2.5.     By Route of administration

8.2.6.     By End User

8.2.7.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Neuroendocrine Tumors Treatment Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapy Type

8.3.1.2.2.             By Mechanism of action

8.3.1.2.3.             By Drug Type

8.3.1.2.4.             By Indication

8.3.1.2.5.             By Route od administration

8.3.1.2.6.             By End User

8.3.2.     Germany Neuroendocrine Tumors Treatment Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapy Type

8.3.2.2.2.             By Mechanism of action

8.3.2.2.3.             By Drug Type

8.3.2.2.4.             By Indication

8.3.2.2.5.             By Route od administration

8.3.2.2.6.             By End User

8.3.3.     United Kingdom Neuroendocrine Tumors Treatment Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapy Type

8.3.3.2.2.             By Mechanism of action

8.3.3.2.3.             By Drug Type

8.3.3.2.4.             By Indication

8.3.3.2.5.             By Route od administration

8.3.3.2.6.             By End User

8.3.4.     Italy Neuroendocrine Tumors Treatment Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapy Type

8.3.4.2.2.             By Mechanism of action

8.3.4.2.3.             By Drug Type

8.3.4.2.4.             By Indication

8.3.4.2.5.             By Route od administration

8.3.4.2.6.             By End User

8.3.5.     Spain Neuroendocrine Tumors Treatment Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapy Type

8.3.5.2.2.             By Mechanism of action

8.3.5.2.3.             By Drug Type

8.3.5.2.4.             By Indication

8.3.5.2.5.             By Route od administration

8.3.5.2.6.             By End User

9.    North America Neuroendocrine Tumors Treatment Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapy Type

9.2.2.     By Mechanism of Action

9.2.3.     By Drug Type

9.2.4.     By Indication

9.2.5.     By Route of administration

9.2.6.     By End User

9.2.7.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Neuroendocrine Tumors Treatment Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapy Type

9.3.1.2.2.             By Mechanism of action

9.3.1.2.3.             By Drug Type

9.3.1.2.4.             By Indication

9.3.1.2.5.             By Route od administration

9.3.1.2.6.             By End User

9.3.2.     Mexico Neuroendocrine Tumors Treatment Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapy Type

9.3.2.2.2.             By Mechanism of action

9.3.2.2.3.             By Drug Type

9.3.2.2.4.             By Indication

9.3.2.2.5.             By Route od administration

9.3.2.2.6.             By End User

9.3.3.     Canada Neuroendocrine Tumors Treatment Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapy Type

9.3.3.2.2.             By Mechanism of action

9.3.3.2.3.             By Drug Type

9.3.3.2.4.             By Indication

9.3.3.2.5.             By Route od administration

9.3.3.2.6.             By End User

10.  South America Neuroendocrine Tumors Treatment Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapy Type

10.2.2.  By Mechanism of Action

10.2.3.  By Drug Type

10.2.4.  By Indication

10.2.5.  By Route of administration

10.2.6.  By End User

10.2.7.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Neuroendocrine Tumors Treatment Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapy Type

10.3.1.2.2.           By Mechanism of action

10.3.1.2.3.           By Drug Type

10.3.1.2.4.           By Indication

10.3.1.2.5.           By Route od administration

10.3.1.2.6.           By End User

10.3.2.  Argentina Neuroendocrine Tumors Treatment Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapy Type

10.3.2.2.2.           By Mechanism of action

10.3.2.2.3.           By Drug Type

10.3.2.2.4.           By Indication

10.3.2.2.5.           By Route od administration

10.3.2.2.6.           By End User

10.3.3.  Colombia Neuroendocrine Tumors Treatment Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapy Type

10.3.3.2.2.           By Mechanism of action

10.3.3.2.3.           By Drug Type

10.3.3.2.4.           By Indication

10.3.3.2.5.           By Route od administration

10.3.3.2.6.           By End User

11.  Middle East and Africa Neuroendocrine Tumors Treatment Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapy Type

11.2.2.  By Mechanism of Action

11.2.3.  By Drug Type

11.2.4.  By Indication

11.2.5.  By Route of administration

11.2.6.  By End User

11.2.7.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Neuroendocrine Tumors Treatment Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapy Type

11.3.1.2.2.           By Mechanism of action

11.3.1.2.3.           By Drug Type

11.3.1.2.4.           By Indication

11.3.1.2.5.           By Route od administration

11.3.1.2.6.           By End User

11.3.2.  Saudi Arabia Neuroendocrine Tumors Treatment Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapy Type

11.3.2.2.2.           By Mechanism of action

11.3.2.2.3.           By Drug Type

11.3.2.2.4.           By Indication

11.3.2.2.5.           By Route od administration

11.3.2.2.6.           By End User

11.3.3.  UAE Neuroendocrine Tumors Treatment Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapy Type

11.3.3.2.2.           By Mechanism of action

11.3.3.2.3.           By Drug Type

11.3.3.2.4.           By Indication

11.3.3.2.5.           By Route od administration

11.3.3.2.6.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled

14.2.1.  F. Hoffmann-La Roche Ltd.

14.2.2.  Bristol-Myers Squibb AB

14.2.3.  Eli Lilly & Company

14.2.4.  Novartis AG

14.2.5.  Pfizer Inc.

14.2.6.  Amgen, Inc.

14.2.7.  Exelixis Inc.

14.2.8.  Teva Pharmaceuticals Ltd.

14.2.9.  Callisto Pharmaceuticals Pvt. Ltd.

14.2.10.                Boehringer Ingelheim GmbH

14.2.11.                Dauntless Pharmaceuticals Inc.

14.2.12.                Hutchison MediPharma Limited

14.2.13.                AVEO Pharmaceuticals, Inc.

14.2.14.                Aegis Therapeutics LLC

14.2.15.                Progenics Pharmaceuticals, Inc.

15.  Strategic Recommendations

16.  About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com